FGTI-2734
- Product Name
- FGTI-2734
- CAS No.
- 1247018-19-4
- Chemical Name
- FGTI-2734
- Synonyms
- FGTI-2734;FGTI-2734, 10 mM in DMSO;N-(2-((4-Cyano-2-fluorophenyl)((1-methyl-1H-imidazol-5-yl)methyl)amino)ethyl)-N-(cyclohexylmethyl)pyridine-2-sulfonamide;2-Pyridinesulfonamide, N-[2-[(4-cyano-2-fluorophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(cyclohexylmethyl)-;pancreatic,patient-derived,geranylgeranyl,farnesyl,inhibit,Farnesyl Transferase,mimetic,FGTI2734,Inhibitor,membrane,Ftase,FGTI-2734,KRAS,FGTI 2734,C-terminal,transferase,tumors,localization
- CBNumber
- CB75540586
- Molecular Formula
- C26H31FN6O2S
- Formula Weight
- 510.63
- MOL File
- 1247018-19-4.mol
FGTI-2734 Property
- Boiling point:
- 770.1±70.0 °C(Predicted)
- Density
- 1.28±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO:50.0(Max Conc. mg/mL);97.92(Max Conc. mM)
- form
- Solid
- pka
- 6.60±0.10(Predicted)
- color
- White to off-white
N-Bromosuccinimide Price
- Product number
- CS-0099052
- Product name
- FGTI-2734
- Purity
- 99.48%
- Packaging
- 5mg
- Price
- $350
- Updated
- 2021/12/16
- Product number
- CS-0099052
- Product name
- FGTI-2734
- Purity
- 99.48%
- Packaging
- 10mg
- Price
- $650
- Updated
- 2021/12/16
- Product number
- CS-0099052
- Product name
- FGTI-2734
- Purity
- 99.48%
- Packaging
- 50mg
- Price
- $2000
- Updated
- 2021/12/16
- Product number
- CS-0099052
- Product name
- FGTI-2734
- Purity
- 99.48%
- Packaging
- 100mg
- Price
- $3500
- Updated
- 2021/12/16
- Product number
- DC32723
- Product name
- FGTI-2734
- Packaging
- 100mg
- Price
- $1300
- Updated
- 2021/12/16
FGTI-2734 Chemical Properties,Usage,Production
Description
FGTI-2734 is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor. It can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors.
Uses
FGTI-2734 is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC50s of 250 nM and 520 nM for FT and GGT-1, respectively. FGTI-2734 can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors[1].
in vivo
FGTI-2734 (intraperitoneally; 100 mg/kg/daily for 18 to 25 days) only inhibits tumor growth in mutant KRAS-dependent tumors but not in mutant KRAS-independent tumors[1].
| Animal Model: | Male SCID-bg mice following injection of MiaPaCa2, L3.6pl, Calu6, A549, H460 and DLD1 cancer cells[1] |
| Dosage: | 100 mg/kg |
| Administration: | Intraperitoneally; daily; for 18 to 25 days |
| Result: | Inhibited tumor growth in mutant KRAS-dependent tumors. |
target
FGTI-2734 is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC50s of 250 nM and 520 nM for FT and GGT-1, respectively.
References
[1] Kazi A, et al. Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors. Clin Cancer Res. 2019 Jun 21. DOI:10.1158/1078-0432.CCR-18-3399
FGTI-2734 Preparation Products And Raw materials
Raw materials
Preparation Products
FGTI-2734 Suppliers
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- +1-781-999-5354;
- support@targetmol.com
- Country
- United States
- ProdList
- 39035
- Advantage
- 58
- Tel
- tp@aladdinsci.com
- Country
- United States
- ProdList
- 52923
- Advantage
- 58